The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
Under this model, C1q is a context decoder whose downstream program depends chiefly on the biochemical identity of the complex it forms, such as neuronal pentraxins, Aβ aggregates, apoptotic membranes, or ECM ligands. Spatial localization remains relevant, but as a secondary variable relative to ligand chemistry and complex composition.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Target Gene: C1QAC1QBC1QCNPTX1NPTX2APPC3"]
B["Molecular Mechanism Pathway Activation"]
C["Cellular Phenotype Neuronal / Glial Response"]
D["Network Effect Circuit-Level Consequence"]
E["Disease Relevance Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for C1QA,C1QB,C1QC,NPTX1,NPTX2,APP,C3 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
C1q binds diverse ligands including Aβ, indicating…
No decisive CNS study yet demonstrates that ligand identity explains more variance than location when ligand, …▼
No decisive CNS study yet demonstrates that ligand identity explains more variance than location when ligand, receiver cell, and complement competence are independently controlled.
Microenvironmental geometry, local complement regulators, and which cell encounters the complex first may riva…▼
Microenvironmental geometry, local complement regulators, and which cell encounters the complex first may rival or exceed ligand identity in determining outcome.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF C1q is pre-incubated with neuronal pentraxin 1 (NPTX1) to form C1q-NPTX1 complexes versus pre-incubated with amyloid-beta (APP-derived Aβ1-42) to form C1q-Aβ complexes, THEN human iPSC-derived cortical neurons will exhibit significantly different transcriptional profiles of complement-related genes (C3, C4B) with C1q-Aβ complexes producing 2-3 fold higher expression within 48 hours.
pendingconf: 0.60
Expected outcome: Differential complement gene expression; C1q-Aβ complexes will upregulate C3 and C4B mRNA 2-3 fold higher than C1q-NPTX1 complexes
Falsified by: If C1q-NPTX1 and C1q-Aβ complexes produce statistically equivalent complement gene expression (difference <1.2-fold, p > 0.05), the hypothesis that binding partner identity is primary would be falsified
Method: Human iPSC-derived cortical neurons (n=4 lines) treated with 100 nM purified C1q pre-complexed to either NPTX1 or Aβ1-42; RNA-seq and qPCR for complement pathway genes at 6, 24, 48 hours
IF C1q is targeted to neuronal dendrites via cell-impermeant crosslinking versus allowed to diffuse freely in extracellular space while binding identical NPTX2 ligand, THEN the downstream complement C3 opsonization rate on hippocampal neurons will remain unchanged (within 15% variance), indicating ligand identity dominates subcellular location within 12 hours.
Falsified by: If targeted C1q-NPTX2 produces ≥40% higher C3 deposition than freely-diffused C1q-NPTX2, location would be the primary determinant rather than ligand identity, falsifying this prediction
Method: Mouse hippocampal neuron culture (E18) with biotinylated C1q-NPTX2 complexes ± streptavidin-anchored targeting to dendritic EphB2 regions; live-cell C3 opsonization assay using fluorophore-labeled C3 antibodies